Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: International Journal of Molecular Sciences 23.15 (2022): 8177.
- Event
-
Veröffentlichung
- (where)
-
Erlangen
- (who)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (when)
-
2022
- Creator
-
Peter, Antonia Sophia
Grüner, Eva
Socher, Eileen
Fraedrich, Kirsten
Richel, Elie
Mueller-Schmucker, Sandra
Cordsmeier, Arne
Ensser, Armin
Sticht, Heinrich
Überla, Klaus
- DOI
-
10.3390/ijms23158177
- URN
-
urn:nbn:de:bvb:29-opus4-206119
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:54 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Peter, Antonia Sophia
- Grüner, Eva
- Socher, Eileen
- Fraedrich, Kirsten
- Richel, Elie
- Mueller-Schmucker, Sandra
- Cordsmeier, Arne
- Ensser, Armin
- Sticht, Heinrich
- Überla, Klaus
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Time of origin
- 2022
Other Objects (12)
Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
Neutralizing antibodies as tools for structure-based vaccine design
A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model
Utility of different surrogate enzyme-linked immunosorbent assays (sELISAs) for detection of SARS-CoV-2 neutralizing antibodies
Identification and characterization of broadly neutralizing antibodies targeting viral infections
Development of neutralizing and non-neutralizing antibodies targeting known and novel epitopes on Clostridioides difficile Toxin B
Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection
Peptide variants of a SARS-CoV-2 neutralizing protein
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
tANCHOR-cell-based assay for monitoring of SARS-CoV-2 neutralizing antibodies rapidly adaptive to various receptor-binding domains
Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
Neutralizing antibodies as tools for structure-based vaccine design
A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model
Utility of different surrogate enzyme-linked immunosorbent assays (sELISAs) for detection of SARS-CoV-2 neutralizing antibodies
Identification and characterization of broadly neutralizing antibodies targeting viral infections
Development of neutralizing and non-neutralizing antibodies targeting known and novel epitopes on Clostridioides difficile Toxin B
Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection
Peptide variants of a SARS-CoV-2 neutralizing protein
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
tANCHOR-cell-based assay for monitoring of SARS-CoV-2 neutralizing antibodies rapidly adaptive to various receptor-binding domains
Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
Neutralizing antibodies as tools for structure-based vaccine design
A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model
Utility of different surrogate enzyme-linked immunosorbent assays (sELISAs) for detection of SARS-CoV-2 neutralizing antibodies
Identification and characterization of broadly neutralizing antibodies targeting viral infections
Development of neutralizing and non-neutralizing antibodies targeting known and novel epitopes on Clostridioides difficile Toxin B
Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection
Peptide variants of a SARS-CoV-2 neutralizing protein
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
tANCHOR-cell-based assay for monitoring of SARS-CoV-2 neutralizing antibodies rapidly adaptive to various receptor-binding domains